Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) (NSEIFSC: DRREDDY) reported on Monday that its wholly-owned subsidiary, Dr. Reddy's Laboratories SA, has entered into a definitive agreement to acquire the US generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited (ASX: MYX).
Under the terms of the agreement, Dr. Reddy's will acquire the portfolio for an upfront payment of approximately USD90m in cash, contingent payments of up to USD15m, consideration towards inventory and credits for certain accrued channel liabilities to be determined on the closing date. Closing of the transaction is subject to satisfactory completion of customary closing conditions.
This portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women's health. Mayne Pharma reported total revenue of USD111m for the acquired portfolio, for the financial period ended 30 June 2022.
According to Dr. Reddy's, approved high-value products in the portfolio include a hormonal vaginal ring, a birth control pill and a cardiovascular product.
Upsher-Smith launches Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%
Torrent Pharma starts shipping generic Keveyis (dichlorphenamide), 50mg tablets in US
Upsher-Smith Laboratories introduces Fluphenazine Hydrochloride Tablets
American Regent launches sulphite-free Epinephrine Injection
Teva and Natco Launch Additional Strengths for the Generic Version of Revlimid in the US
Accord Healthcare adds Teriflunomide to oral medications range